Gene therapy of metastatic cancer by in vivo retroviral gene targeting

We have achieved efficient transduction of tumour metastases in vivo by the vascular delivery of retroviral producer cells. Experimental liver metastases in mice were created by intrasplenic injection of tumour cells into the portal venous circulation. Following the establishment of micrometastases, delivery of retroviral producer cells by the same route with a vector containing the Escherichia coli −galactosidase (lacZ) gene demonstrated selective in vivo gene transfer to tumour deposits. By this approach, two retroviral producer cell lines encoding cytokines (IL−4 and IL−2) directed tumoricidal inflammatory responses to established metastases. Cytokine gene targeting inhibited metastasis formation and caused significant overall reduction in tumour burden. These results suggest a novel therapeutic approach for the treatment of disseminated cancer.

1. Tepper, R.I. & Mule, J.J. Experimental and clinical studies of cytokine gene-modified tumour cells. Hum. Gene Ther. 5, 153−164 (1994). | PubMed  | ISI | ChemPort |
2. Dranoff, G. et al. Vaccination with irradiated tumour cells engineered to secrete murinegranulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity. Proc. natn. Acad. Sci. U.S.A. 90, 3539−3543 (1993). | ChemPort |
3. Culver, K.W. et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumours. Science 256, 1550−1552 (1992). | PubMed  | ISI | ChemPort |
4. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. & Oldfield, E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumours in rats. Cancer Res. 53, 83−88 (1993). | PubMed  | ISI | ChemPort |
5. Caruso, M. et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. natn. Acad. Sci. U.S.A. 90, 7024−7028 (1993). | ChemPort |
6. Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. & Woo, S.L.C. Gene therapy for brain tumours: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. natn. Acad. Sci. U.S.A. 91, 3054−3057 (1994). | ChemPort |
7. Nabel, G.J. et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. natn. Acad. Sci. U.S.A. 90, 11307−11311 (1993). | ChemPort |
8. Miller, D.G., Adam, M.A. & Miller, A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Molec. cell. Biol. 10, 4239−4242 (1990). | PubMed  | ISI | ChemPort |
9. Tepper, R.I., Pattengale, P.K. & Leder, P. Murine interleukin-4 displays potent anti-tumour activity in vivo. Cell 57, 503−512 (1989). | Article | PubMed  | ISI | ChemPort |
10. Tepper, R.I., Coffman, R.L. & Leder, P. An eosinophil-dependent mechanism for the antitumour effect of interleukin-4. Science 257, 548−551 (1992). | PubMed  | ISI | ChemPort |
11. Fearon, E.R. et al. Interleukin-2 production by tumour cells bypasses T helper function in the generation of an antitumour response. Cell 60, 397−403 (1990). | Article | PubMed  | ISI | ChemPort |
12. Gansbacher, B. et al. Interleukin 2 gene transfer into tumour cells abrogates tumourigenicity and induces protective immunity. J. exp. Med. 172, 1217−1224 (1990). | Article | PubMed  | ISI | ChemPort |
13. Danos, O. & Mulligan, R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. natn. Acad. Sci. U.S.A. 85, 6460−6464 (1988). | ChemPort |
14. Takeuchi, Y. et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001−8007 (1994). | PubMed  | ISI | ChemPort |
15. Karp, S.E. et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: tumour inhibition by IL-2 but not tumour necrosis factor. J. Immunol. 150, 896−908 (1993). | PubMed  | ISI | ChemPort |
16. Kaleko, M., Garcia, J.V., Osbome, W.R.A. & Miller, A.D. Expression of human adenosine deaminase in mice after transplantation of genetically-modifiedbone marrow. Blood 75, 1733−1741 (1990). | PubMed  | ISI | ChemPort |
17. Hu-Li, J., Ohara, J., Watson, C., Tsang, W. & Paul, W.E. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT. 4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J. Immunol. 142, 800−807 (1989). | PubMed  | ChemPort |
18. Kay, M.A. et al. In vivo gene therapy of Hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 262, 117−119 (1993). | PubMed  | ISI | ChemPort |

	Top

	Top